1. Elucidation of mechanisms of actions of thymoquinone-enriched methanolic and volatile oil extracts from Nigella sativa against cardiovascular risk parameters in experimental hyperlipidemia
   Shafeeque Ahmad et al, 2013, Lipids in Health and Disease CrossRef
2. Effects of CBD supplementation on ambulatory blood pressure and serum urotensin-II concentrations in Caucasian patients with essential hypertension: A sub-analysis of the HYPER-H21-4 trial
   Marko Kumric et al, 2023, Biomedicine & Pharmacotherapy CrossRef
3. The peptide compound urantide regulates collagen metabolism in atherosclerotic rat hearts and inhibits the JAK2/STAT3 pathway
   Tu Wang et al, 2020, Molecular Medicine Reports CrossRef
4. Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats
   JUAN ZHAO et al, 2014, Experimental and Therapeutic Medicine CrossRef
5. Identifying Circulating Urotensin II and Urotensin II-Related Peptide-Generating Enzymes in the Human Plasma Fraction Cohn IV-4
   Raphael Schuster et al, 2021, Journal of Proteome Research CrossRef
6. Development and Pharmacological Characterization of Conformationally Constrained Urotensin II-Related Peptide Agonists
   David Chatenet et al, 2013, Journal of Medicinal Chemistry CrossRef
7. Urotensin-II As a Promising Key-Point of Cardiovascular Disturbances Sequel
   Ashot Avagimyan et al, 2022, Current Problems in Cardiology CrossRef
8. Urantide Conformation and Interaction with the Urotensin‐II Receptor
   Diego Brancaccio et al, 2014, Archiv der Pharmazie CrossRef
9. Crocin alleviates coronary atherosclerosis via inhibiting lipid synthesis and inducing M2 macrophage polarization
   Jing Li et al, 2018, International Immunopharmacology CrossRef
10. Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats
    Tu Wang et al, 2020, Life Sciences CrossRef
11. Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway
    Juan Zhao et al, 2020, Life Sciences CrossRef
12. Structure–Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position 9
    Francesco Merlino et al, 2016, ChemMedChem CrossRef
13. Comparative pre- and post-treatment effects of Nigella sativa oil on lipid profile and antioxidant enzymes in a rat model of diabetes mellitus
    AbdullahiA. Adejare et al, 2020, Nigerian Journal of Medicine CrossRef
14. UII/GPR14 is involved in NF-κB-mediated colonic inflammation in vivo and in vitro
    Yi Yang et al, 2016, Oncology Reports CrossRef
15. Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor
    Alfonso Carotenuto et al, 2014, Journal of Medicinal Chemistry CrossRef
16. Urotensin II: an inflammatory cytokine
    Shui-lin Sun et al, 2019, Journal of Endocrinology CrossRef
17. Novel insights into the role of urotensin II in cardiovascular disease
    João Pereira-Castro et al, 2019, Drug Discovery Today CrossRef
18. A novel urotensin II receptor antagonist, KR-36676, prevents ABCA1 repression via ERK/IL-1β pathway
    Mi-Young Kim et al, 2017, European Journal of Pharmacology CrossRef
19. Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands
    Hassan Nassour et al, 2021, Journal of Biological Chemistry CrossRef
20. Urantide protects CCl4-induced liver injury via inhibiting GPR14 signal in mice
    Haiying Sun et al, 2017, Biotechnology & Biotechnological Equipment CrossRef
21. Urotensin II(4–11) Azasulfuryl Peptides: Synthesis and Biological Activity
    Francesco Merlino et al, 2016, Journal of Medicinal Chemistry CrossRef